Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9718893 Bispecific antibody molecule

Patent 9718893 was granted and assigned to SYNIMMUNE GmbH on August, 2017 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Current Assignee

‌

SYNIMMUNE GmbH

Date Filed

November 12, 2012

Date of Patent

August 1, 2017

Patent Applicant

‌

SYNIMMUNE GmbH

Patent Application Number

14366669

Patent Citations Received

‌

US Patent 11976117 T cell-antigen coupler with various construct optimizations

‌

US Patent 11834506 Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer

‌

US Patent 11859010 Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

‌

US Patent 11878035 T cell-antigen coupler with various construct optimizations

‌

US Patent 11884720 Antibody constructs for MSLN and CD3

‌

US Patent 11884732 Proteins binding HER2, NKG2D and CD16

‌

US Patent 11884733 Antibody variable domains targeting the NKG2D receptor

‌

US Patent 11939384 Antibody variable domains targeting the NKG2D receptor

‌

US Patent 11970545 T cell-antigen coupler with Y182T mutation and methods of uses thereof

‌

US Patent 12129300 Antibody variable domains targeting the NKG2D receptor

•••

Patent Inventor Names

Michael Durben

Gundram Jung

Ludger Grosse-Hovest

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9718893

Patent Primary Examiner

‌

Lynn Bristol

Find more entities like US Patent 9718893 Bispecific antibody molecule

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API

By using this site, you agree to our Terms of Service.